Alcoholic Liver Disease, MASLD, and MASH: A Practical Clinical Guide

What Is Alcoholic Liver Disease?

Alcoholic liver disease (ALD) is a spectrum of liver injury caused directly by chronic or heavy alcohol consumption. The three main stages are alcoholic fatty liver (steatosis), alcoholic hepatitis, and alcoholic cirrhosis. All three can coexist. Alcohol is metabolized in the liver to acetaldehyde, a toxic compound that triggers oxidative stress, mitochondrial dysfunction, and inflammatory cytokine release, each of which damages hepatocytes and, over time, activates stellate cells to lay down fibrotic scar tissue [1].

Steatosis alone is common and largely reversible with abstinence. Alcoholic hepatitis, by contrast, is an acute inflammatory syndrome that carries real mortality risk. The Maddrey Discriminant Function (MDF) score stratifies severity: an MDF >32 defines severe disease and is associated with a 30-day mortality of 30-50% without treatment [2]. The National Institute on Alcohol Abuse and Alcoholism notes that prednisolone 40 mg/day for 28 days is the standard of care for severe alcoholic hepatitis when infection has been excluded [3]. The STOPAH trial (N=1,103) found prednisolone reduced 28-day mortality by roughly 46% relative to placebo, though no survival benefit persisted at 90 days or one year [4].

Alcohol abstinence is the single most effective intervention at every stage. Patients who achieve sustained abstinence after an episode of severe alcoholic hepatitis improve their one-year survival by more than 50% compared with those who continue drinking [2].

MASLD: The Renamed, Metabolically Defined Spectrum

MASLD (metabolic dysfunction-associated steatotic liver disease) replaced the older term NAFLD in 2023 following an international consensus process published in Hepatology and endorsed by major liver societies. The name change was not cosmetic. "NAFLD" defined the condition by what it was not (alcohol-related), while "MASLD" defines it by what it actually is: a condition driven by metabolic dysfunction including obesity, insulin resistance, dyslipidemia, and hypertension [5].

To meet the MASLD diagnosis, a patient must have hepatic steatosis (fat in more than 5% of hepatocytes) plus at least one of five cardiometabolic risk factors: BMI >25 kg/m², fasting glucose >100 mg/dL or diagnosed type 2 diabetes, blood pressure >130/85 mmHg, plasma triglycerides >150 mg/dL, or HDL <40 mg/dL in men / <50 mg/dL in women [5]. Patients who consume alcohol above threshold amounts (more than 14 standard drinks per week in men, more than 7 in women) move into the MetALD category under the new nomenclature.

Globally, MASLD affects an estimated 1.5 billion people, with the highest rates in the Americas (44%) and Middle East (42%) [6]. In the United States, MASLD prevalence tracks closely with type 2 diabetes, where it affects 55-70% of patients with T2D [7].

MASH: The Inflammatory Subtype That Carries Real Fibrosis Risk

MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) is the inflammatory subtype of MASLD and the stage at which fibrosis progression accelerates meaningfully. The distinction matters clinically. Simple steatosis alone has a low annual fibrosis progression rate of roughly 0.07 fibrosis stages per year, while MASH advances at approximately 0.14 stages per year, nearly double [8].

Histologically, MASH requires steatosis plus lobular inflammation plus hepatocyte ballooning. A formal diagnosis still requires a liver biopsy, though non-invasive tests such as the FIB-4 index, liver stiffness measurement by vibration-controlled transient elastography (VCTE), and the Enhanced Liver Fibrosis (ELF) score are increasingly used to triage patients and avoid unnecessary biopsy [9].

The AASLD 2023 Practice Guidance states: "Patients with MASH and fibrosis stage F2 or higher should be prioritized for pharmacologic therapy trials and specialist referral" [9]. Patients with F3-F4 fibrosis have a substantially higher 10-year risk of liver-related events including decompensation, hepatocellular carcinoma, and liver transplantation.

Hepatic Steatosis: Imaging, Biomarkers, and Grading

Hepatic steatosis is the foundational lesion across all fatty liver conditions. Fat deposition begins when the rate of fatty acid delivery to the liver (from dietary fat, de novo lipogenesis, and adipose tissue lipolysis) exceeds its oxidative and secretory capacity. Ultrasound is the most common first-line imaging method, with a sensitivity of about 85% and specificity of 95% for steatosis exceeding 20-30% of liver volume, but it cannot reliably grade fibrosis [10].

MRI-based proton density fat fraction (MRI-PDFF) is more accurate across all grades, detecting as little as 5% hepatic fat content with high reproducibility. Controlled attenuation parameter (CAP) measured during transient elastography offers a practical, point-of-care alternative. FibroScan-derived CAP values above 302 dB/m correspond to S2-S3 steatosis in most published cut-off analyses [10].

Blood-based panels add metabolic context. The Fatty Liver Index (FLI), which uses BMI, waist circumference, triglycerides, and gamma-glutamyltransferase (GGT), distinguishes patients who are unlikely to have steatosis (FLI <30) from those who probably do (FLI >60) [11]. FLI does not replace imaging but helps prioritize who needs further workup in primary care.

Cirrhosis: The End-Stage Outcome Both ALD and MASH Share

Cirrhosis is irreversible architectural distortion of the liver caused by progressive fibrosis replacing normal hepatocyte-rich tissue with dense collagen. Both ALD and MASH are leading etiologies of cirrhosis in Western countries. MASLD-related cirrhosis is now the fastest-growing indication for liver transplant evaluation in the United States [12].

Child-Pugh score and the Model for End-Stage Liver Disease (MELD) score guide clinical decision-making. A MELD score above 15 generally indicates a survival benefit from transplant listing. Patients with cirrhosis require semi-annual hepatocellular carcinoma (HCC) surveillance using abdominal ultrasound plus or minus serum alpha-fetoprotein (AFP), per AASLD guidelines [9]. Esophageal varices screening via upper endoscopy is recommended at the time of cirrhosis diagnosis, then every 1-3 years depending on findings.

Early fibrosis (F1-F2) regression is documented in both ALD and MASH when the underlying cause is removed or well-controlled. A 2017 meta-analysis (N=502 paired biopsies) found fibrosis regression occurred in 26% of NASH patients who achieved significant weight loss over two years [13]. Established cirrhosis does not regress meaningfully, which is why earlier intervention carries the greater clinical payoff.

Weight Loss, Diet, and Lifestyle: The Evidence

Weight loss is the most consistently effective non-pharmacologic treatment for MASLD and MASH. The dose-response relationship is clear and well-established. A 3-5% reduction in body weight reduces hepatic steatosis. Reaching 7-10% reduces liver inflammation and ballooning. Achieving 10% or more results in fibrosis regression in a meaningful proportion of patients, based on a paired-biopsy study by Vilar-Gomez et al. (N=261), where 10%+ weight loss led to fibrosis regression in 45% of MASH patients [14].

Diet composition matters alongside total caloric restriction. A Mediterranean-style eating pattern with high olive oil, oily fish, legumes, and vegetables has been shown to reduce hepatic fat independent of weight change. In a randomized controlled trial (N=278), Mediterranean diet reduced liver fat by 29% at 18 months compared with 7% on a low-fat diet [15]. Alcohol reduction or elimination is additive in patients with MetALD or any concurrent alcohol use.

Aerobic exercise at 150-300 minutes per week of moderate intensity reduces intrahepatic triglyceride content even without weight change. Resistance training produces similar hepatic benefits. The two together appear to produce additive reductions in liver stiffness [16].

Pharmacotherapy: Resmetirom, GLP-1 Agonists, and Emerging Agents

Until March 2024, no drug was FDA-approved specifically for MASH with fibrosis. That changed with resmetirom (Rezdiffra), a liver-directed thyroid hormone receptor-beta (THR-beta) agonist. The MAESTRO-NASH trial (N=966) showed resmetirom 100 mg daily achieved MASH resolution in 29.9% of patients vs. 9.7% placebo (P<0.001) and fibrosis improvement by at least one stage in 25.9% vs. 14.2% [17]. The FDA approved resmetirom for adult patients with non-cirrhotic MASH and moderate-to-advanced fibrosis (F2-F3) [17].

GLP-1 receptor agonists have strong and growing evidence in MASH. The ESSENCE phase 3 trial evaluated semaglutide 2.4 mg subcutaneous weekly in patients with biopsy-confirmed MASH and fibrosis stages F2-F3. MASH resolution without worsening fibrosis occurred in 62.9% of the semaglutide group vs. 34.3% of placebo (P<0.001). Fibrosis improvement by at least one stage was seen in 36.8% vs. 22.4% [18]. As of the writing of this article, semaglutide does not yet carry an FDA indication specifically for MASH, though the ESSENCE results are likely to support a regulatory submission.

Semaglutide under the brand name Wegovy is FDA-approved for chronic weight management in adults with BMI >30 or BMI >27 with at least one weight-related comorbidity. Given that MASLD and MASH are metabolic comorbidities of obesity, many clinicians prescribe Wegovy or Ozempic off-label for patients in whom weight loss is the primary hepatic therapeutic strategy [19].

Pioglitazone (a thiazolidinedione) is supported by the PIVENS trial (N=247), which showed it improved NASH histology in patients without diabetes [20]. The AASLD 2023 guidance supports its use in MASH patients with prediabetes or T2D, though weight gain is a consistent side effect. Vitamin E 800 IU/day showed histologic benefit in non-diabetic MASH patients in the same trial but is not used in patients with diabetes, cirrhosis, or hepatocellular carcinoma risk.

Several agents are in late-stage development. Lanifibranor (a pan-PPAR agonist) showed benefit in the NATIVE trial. Obeticholic acid narrowly missed its primary fibrosis endpoint in REGENERATE at 18 months on a per-protocol analysis, and its development in MASH has been discontinued. The field is moving quickly.

The HealthRX Liver Risk Stratification Framework

Clinicians and patients often face a practical gap: how urgently does a given patient with incidentally detected fatty liver need hepatology involvement? The following three-tier framework consolidates current AASLD and European Association for the Study of the Liver (EASL) guidance into actionable triage thresholds.

Tier 1 (Primary Care Management): FIB-4 <1.30, no diabetes, no ALT >2x ULN, no obesity class II or III. These patients have low fibrosis probability. Lifestyle counseling, annual metabolic panel, and repeat FIB-4 in 2-3 years is appropriate.

Tier 2 (Gastroenterology or Hepatology Referral Within 6 Months): FIB-4 1.30-2.67, OR any of: type 2 diabetes with suspected MASLD, ALT persistently >2x ULN, liver stiffness 8-12 kPa on VCTE. These patients need non-invasive fibrosis staging, possible liver biopsy consideration, and pharmacotherapy discussion.

Tier 3 (Urgent Hepatology Referral, Within 4 Weeks): FIB-4 >2.67, liver stiffness >12 kPa, platelet count <150,000 (possible portal hypertension), any clinical decompensation (ascites, encephalopathy, variceal bleed), or suspected alcoholic hepatitis. These patients need cirrhosis workup, MELD scoring, HCC surveillance initiation, and possible transplant evaluation.

Alcoholic Liver Disease: Specific Management Steps

ALD management diverges from MASLD in several important ways. Abstinence from alcohol is non-negotiable at every stage and has no pharmacologic substitute. For patients with alcohol use disorder (AUD), pharmacotherapy to support abstinence should be offered concurrently with liver treatment. Naltrexone 50 mg/day (avoid in acute hepatitis) and acamprosate 666 mg three times daily are FDA-approved for AUD and carry acceptable hepatic safety profiles in compensated liver disease [3].

Nutritional support is a central concern in alcoholic hepatitis and cirrhosis. Protein-calorie malnutrition is present in up to 100% of patients with severe alcoholic hepatitis. Enteral nutrition via nasogastric tube should be initiated within 24-48 hours in patients who cannot meet 35-40 kcal/kg/day orally. In the STOPAH trial, no survival advantage was found for pentoxifylline vs. placebo, confirming that prednisolone (when not contraindicated) remains the only pharmacotherapy with proven short-term mortality benefit in severe ALD [4].

N-acetylcysteine added to prednisolone was evaluated in a French RCT (N=174), which showed a 30-day survival benefit (78% vs. 63%, P=0.02), though no benefit persisted at 6 months [21]. It is sometimes used adjunctively given its favorable safety profile.

Patients with ALD-related cirrhosis who achieve sustained alcohol abstinence and have sufficient hepatic reserve may be considered for liver transplantation after typically at least 6 months of abstinence, though early transplant protocols at selected centers are shortening this window for carefully selected patients who fail medical management.

Monitoring and Long-Term Follow-Up

Patients diagnosed with MASLD or ALD at any fibrosis stage require structured follow-up. The key parameters to track are: serial liver enzymes (ALT, AST, GGT), platelet count as a portal hypertension proxy, metabolic panel (fasting glucose, HbA1c, lipid panel), body weight and waist circumference, and repeat non-invasive fibrosis assessment every 1-2 years in those with F0-F2 disease.

Patients on resmetirom need lipid monitoring at 4 and 12 weeks after initiation, the drug reduces LDL-C substantially, which may require statin dose adjustment. GLP-1 receptor agonists in this population require standard GI tolerability monitoring and HbA1c tracking if diabetes is present.

HCC risk exists even in non-cirrhotic MASH at fibrosis stage F3, though the absolute annual incidence (<1%) is substantially lower than in cirrhosis (1-4%). AASLD does not recommend routine surveillance below cirrhosis unless additional risk factors (such as type 2 diabetes, age >50, and male sex) are present [9].

A target of 10% body-weight loss over 6-12 months remains the most meaningful clinical goal for patients with MASH and fibrosis, based on the Vilar-Gomez paired-biopsy data showing fibrosis regression in 45% of patients who achieved this threshold [14].